It was a great pleasure for me and my co-chairman, Professor Peter Sever, to welcome all of the many participants to the Takeda-sponsored symposium entitled 'Angiotensin II Receptor Antagonists are NOT all the same' which was recently held in Amsterdam, on 6 June 1998, as part of the 17th ISH Meeting. This was the third symposium focusing on angiotensin II receptors in a series which started 4 years ago in Melbourne. The impetus for initiating these symposia was the increasing interest shown by clinicians working in the field of hypertension in the angiotensin antagonists, as more specific actions of these compounds were recognised in comparison to the ACE inhibitors. The original non-peptide angiotensin antagonists which engendered a surge of interest was CV-2961. Although too weak to apply clinically, it ignited a great deal of research in this field. Now, only a short 4 years later, there are several angiotensin antagonists available for clinical use due to the great deal of progress made in this field, both in basic science and clinical investigation. This symposium was very fortunate in having distinguished scientists renowned for their work in this area, present their latest research findings.
Angiotensin II antagonists are a highly exciting and relatively new class of drugs with a great potential for clinical use in the field of cardiovascular and renal disease. We are pleased to provide the reader with reports from eminent clinicians and researchers who presented their findings. These presentations covered three major areas. The first looked at new refinements in the approach to hypertension management with reference to the latest preclinical and clinical studies. Included in this section were reports giving perspectives from German, and Japanese doctors. Professor Unger (Kiel, Germany)
Correspondence: Professor K Arakawa, Second Department of Internal Medicine, Fukuoka University School of Medicine, 7-45-1 Nanakuma Jonan-ku, Fukuoka 814-0133, Japan looked at angiotensin II-receptor pharmacology and AT 1 -receptor blocker, while Professor Miyazaki (Osaka, Japan) covered the effect of candesartan cilexetil on canine intima hyperplasia after balloon injury, comparing ACE inhibitors with angiotensin II receptor antagonists. Professor Ogihara (Osaka, Japan) finished this first session with an in-depth look at the clinical efficacy and tolerability of the angiotensin II-receptor antagonist, candesartan cilexetil, in the treatment of hypertension.
The second session focused on the issue of organ protection, and provided the audience with some extremely interesting state-of-the-art information. Professor Mallion (Grenoble, France) discussed the cardiac and vascular remodelling effect of antihypertensive agents. This was followed by Dr Yamazaki (Tokyo, Japan) who presented ground-breaking work on the role of tissue angiotensin II in myocardial remodelling induced by mechanical stress. Professor Brenner (Boston, USA) added to this by looking at ACE-I versus angiotensin II-receptor antagonists in regard to prevention of renal injury using information gained from chronic rat models. The role of candesartan in the renal system was further elucidated by Professor Kurokawa (Isehara, Japan) who described the effects of candesartan on the proteinuria of chronic glomerulonephritis.
Specific information on candesartan cilexetil was presented in the final session, with the key features of this new, and potentially very useful drug, presented by Professor Sever (London, UK). Professor Sever's presentation appears at the beginning of this supplement as an overview of the symposium presentations. In a stimulating end to the symposium, additional topics included the effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats from Professor Akio Fujimura (Tochigi, Japan); the effect of candesartan cilexetil on insulin sensitivity and pressor mechanisms in essential hypertension from
